Compare Inovio Pharmaceuticals Inc (INO) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Oxford Lane Capital Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while Oxford Lane Capital Corp trades at $8.82 (market cap $866.15M). The key difference: Oxford Lane Capital Corp is far larger — about 9.7× Inovio Pharmaceuticals Inc's market cap, and Oxford Lane Capital Corp pays a 27.06% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | OXLC | |
|---|---|---|
Market Cap | $89.27M | $866.15M |
Sector | Health | Financials |
52-Week High | $2.87 | $19.90 |
52-Week Low | $1.05 | $8.15 |
Enterprise Value | $60.28M | — |
Dividend Yield | — | 27.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
